...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
【24h】

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

机译：ABT-335（非诺贝特酸）联合阿托伐他汀治疗混合型血脂异常的疗效和安全性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol <40 mg/dl for men and <50 mg/dl for women were randomly assigned to ABT-335 (135 mg), atorvastatin (20, 40, or 80 mg), or combination therapy (ABT-335 + atorvastatin 20 or 40 mg) and treated for 12 weeks. Combination therapy with ABT-335 + atorvastatin 20 mg resulted in significantly greater improvements in TG (-45.6% vs -16.5%) and HDL cholesterol (14.0% vs 6.3%) compared with atorvastatin 20 mg and LDL cholesterol (-33.7% vs -3.4%) compared with ABT-335. Similarly, significantly greater improvements were observed with ABT-335 + atorvastatin 40 mg in TG (-42.1% vs -23.2%) and HDL cholesterol (12.6% vs 5.3%) compared with atorvastatin 40 mg and LDL cholesterol (-35.4% vs -3.4%) compared with ABT-335 monotherapy. Combination therapy also improved multiple secondary variables. Combination therapy was generally well tolerated with a safety profile consistent with those of ABT-335 and atorvastatin monotherapies. No rhabdomyolysis was reported. In conclusion, ABT-335 + atorvastatin combination therapy resulted in more effective control of multiple lipid parameters than either monotherapy and may be an appropriate therapy for patients with mixed dyslipidemia.
机译：在以甘油三酸酯（TG）升高，高密度脂蛋白（HDL）胆固醇降低和低密度脂蛋白（LDL）胆固醇升高为特征的混合血脂异常患者中，用改变脂类药物的单一疗法通常无法达到所有的脂质目标。这项多中心，双盲，主动对照研究评估了混合性血脂异常患者的ABT-335（非诺贝酸）与2剂阿托伐他汀的组合。总共613例LDL胆固醇>或= 130 mg / dl，TG>或= 150 mg / dl，HDL胆固醇<40 mg / dl，女性<50 mg / dl的患者被随机分配到ABT-335 （135毫克），阿托伐他汀（20、40或80毫克）或联合疗法（ABT-335 +阿托伐他汀20或40毫克）治疗12周。与20毫克阿托伐他汀和LDL胆固醇（-33.7％相对-- 3.4％）与ABT-335相比。同样，与40毫克阿托伐他汀和LDL胆固醇（-35.4％vs-）相比，ABT-335 +阿托伐他汀40 mg TG（-42.1％vs -23.2％）和HDL胆固醇（12.6％vs 5.3％）的改善明显更大。与ABT-335单药治疗相比，占3.4％）。联合疗法还改善了多个继发变量。组合疗法通常耐受性良好，其安全性与ABT-335和阿托伐他汀单一疗法一致。没有横纹肌溶解的报道。总之，与任一单一疗法相比，ABT-335 +阿托伐他汀联合疗法可有效控制多种脂质参数，可能是混合血脂异常患者的合适疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号